Skip to main content

Table 3 Baseline features of the studies included

From: Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies

Studies

Mean age

Males (%)

HT (%)

Ds (%)

Cs (%)

 

S/L

S/L

S/L

S/L

S/L

Brar2008

62.9/62.9

70.0/70.0

-

-

-

I-LOVE IT 2

60.4/60.0

67.2/68.7

61.0/64.8

25.3/23.4

24.2/24.9

ISAR-SAFE

67.2/67.2

80.7/80.5

90.1/91.5

87.5/87.4

24.9/25.7

Tarantini2016

65.5/66.7

71.8/74.0

82.5/80.3

69.4/70.9

18.9/20.2

ARCTIC

64.0/64.0

81.0/80.0

62.0/59.0

68.0/67.0

24.0/23.0

OPTIMIZE

61.3/61.9

63.5/63.1

86.4/88.2

63.2/63.7

18.6/17.3

RESET

62.4/62.4

64.4/62.9

62.3/61.4

57.7/59.9

25.2/22.8

EXCELLENT

63.0/62.4

65.1/63.9

72.7/73.8

75.2/76.3

27.4/25.8

PEGASUS

65.0/66.0

77.0/77.0

76.0/76.0

76.0/77.0

16.0/17.0

DAPT

61.6/61.8

74.0/75.3

74.0/75.8

-

24.7/24.6

Sardella2011

61.9/61.2

78.2/81.3

76.7/74.8

57.1/64.0

48.1/62.6

PRODIGY

70.0/68.0

75.0/78.0

71.0/72.0

62.0/66.0

12.0/15.0

Thukkani2015

64.3/64.3

98.5/98.5

97.1/97.8

-

34.8/33.3

ENDEAVOR

62.4/63.6

69.6/69.4

73.6/79.5

80.5/81.4

52.3/56.2

ITALIC

61.7/61.5

80.8/79.2

65.2/64.7

67.1/67.1

50.9/52.7

  1. Abbreviations: S short term DAPT use, L prolonged DAPT use, HT hypertension, Ds dyslipidemia, Cs current smoking